百时美施贵宝Bristol Myers Squibb Co. (BMY) 2017年年度报告「NYSE」.pdf

1、“KNOWING THERES A TEAM OF CARING EXPERTS GIVES ME HOPE AND LETS ME EMBRACE A LIFE NOT DEFINED BY MY DISEASE.”Mitra GhandeharizadehThe patient stories shared in this Annual Report depict individual patient responses to our medicines or investigational compounds and are not representative of all patie

2、nt responses.In addition,there is no guarantee that potential drugs or indications still in development will receive regulatory approval.On the cover:Mitra Ghandeharizadeh.See Mitras story on page 5.“SEEING MY DAUGHTERS COURAGE EVERY DAY FILLS ME WITH DETERMINATION TO DEVELOP EFFECTIVE TREATMENTS FO

3、R OUR PATIENTS.”Faranak Nikfar,Ph.D.BRISTOL-MYERS SQUIBB RESEARCH FELLOW DEVELOPING DRUG PRODUCTS FOR TREATMENT OF AUTOIMMUNE DISORDERS AND ONCOLOGYAND MOTHER OF MITRA GHANDEHARIZADEH(FRONT COVER).READ THEIR STORY ON PAGE 5.Bristol-Myers Squibb 2017 Annual Report|1|GLOBAL SALESUNITED STATES 55%EUROP

4、E 24%REST OF THE WORLD21%SERVING OUR PATIENTSThroughout 2017,we drove superior commercial execution,ending the year with$20.8 billion in revenues a 7 percent increase over 2016.Our business focused on areas of unmet need where we are making a big difference.The treatment of cancer remains a critical

5、 focus of our work.Our immuno-oncology portfolio has played a key role,establishing Opdivo as a foundational therapy with significant potential to grow even further.Now approved in nine tumor types and 15 indications,*Opdivo sales grew by 31 percent,ending the year with$4.9 billion in global sales.F

6、urther,this immuno-oncology medicine remains a leading treatment in second-line non-small cell lung cancer and in second-line renal cancer.Alone To Our ShareholdersFor us,its all about our patients.Our mission is focused on patients.Our science is driven by patients.What we do.How we do it.Everythin